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PENGGENOTIPAN POLIMORFISME NUKLEOTIDA TUNGGAL (SNP) PADA 
GEN CTLA-4 DAN GEN FOXP3 DALAM LIMFATIK FILARIASIS DAN 
SCHISTOSOMIASIS 
 
ABSTRAK 
 
Filariasis limfatik (LF) merupakan sejenis penyakit jangkitan parasit yang 
disebabkan oleh cacing halus daripada spesis Brugia dan Wuchereria yang hidup di 
dalam sistem limfatik manusia. Penyakit ini adalah penyumbang terbesar kepada 
ketidakmampuan dan perubahan kekal kepada pesakit yang tinggal di kawasan 
endemik. Manakala penyakit schistosomiasis pula yang disebabkan oleh cacing dari 
spesis Schistosoma, merupakan salah satu daripada penyakit jangkitan parasit 
yang paling kerap berlaku di dunia; yang menyebabkan kerosakan pada organ 
dalaman dan menyekat kadar pembesaran kepada kanak-kanak. Kecenderungan 
terhadap infeksi dan keterukkan penyakit berhubung kait dengan kepelbagaian 
variasi genetik manusia. Walau bagaimanapun, perkaitan ini masih belum dikaji 
terutamanya pada gen CTLA-4 dan gen FoxP3 yang diekspreskan oleh Tregs, 
untuk fungsi dan sumbangan gen-gen ini terhadap risiko infeksi helminth yang 
kronik. Pendekatan penggenotipan SNP telah digunakan dalam kajian ini bagi 
mengenalpasti SNP dalam LF yang disebabkan oleh Brugia malayi dan 
schistosomiasis yang disebabkan oleh Schistosoma haematobium. Secara 
ringkasnya, kaedah kajian ini melibatkan pengestrakkan dan pengkuantitian sampel-
sampel DNA daripada kumpulan terinfeksi parasit dan kumpulan kawalan sihat 
daripada kawasan endemik yang terlibat. Kemudian, dengan menggunakan lima 
SNP daripada gen CTLA-4 dan satu SNP daripada gen FoxP3, sampel-sampel bagi 
kawalan positif telah dipilih dengan menjalankan penggenotipan berskala kecil 
dengan real-time PCR terhadap sepuluh sampel dan seterusnya diikuti dengan 
analisa pengesahan jujukan dan penjajaran DNA. Selepas itu, penggenotipan 
 xiii
berskala besar telah dilakukan ke atas semua sampel. Akhirnya, analisis terhadap 
genotip telah dijalankan menggunakan beberapa kaedah statistik. Pengesahan 
genotip melalui penjujukan ke atas tiga kawalan positif iaitu 6944W, 6725H dan 20M 
didapati mempunyai keputusan yang konsisten dengan keputusan yang diperolehi 
daripada real-time PCR. Empat daripada enam sampel kawalan positif (6725H, 
6944W, 8209H dan 20M) yang tidak mencukupi sumber DNA telah berjaya 
diklonkan. Analisis penjujukan dan kromatogram plasmid telah mengesahkan 
genotip yang dijangka. Penggenotipan berskala besar telah berjaya dijalankan ke 
atas 571 sampel pesakit dan kawalan. Dengan menggunakan ujian chi-square bagi 
menganalisa frekuensi alel, signifikasi yang rendah di lihat ke atas pesakit LF yang 
membawa rs733618G dibandingkan dengan kawalan sihat (P= 0.032). Didapati 
hanya rs16840252 yang tidak signifikan daripada lima SNPs dalam kumpulan 
schistosomiasis apabila dibanding dengan kumpulan kawalan sihat. Analisa taburan 
genotip menunjukkan perbezaan yang signifikan (P= 0.013) di antara pesakit LF 
dengan kawalan sihat bagi rs733618. Sementara itu bagi sampel daripada kawasan 
endemik schistosoma, julat ‘odd ratio’ (OR) bagi taburan genotip untuk semua SNP 
kecuali bagi rs16840252 dan rs231775 adalah menaik dari 0.61 ke 5.65 bagi pesakit 
apabila dibandingkan dengan kawalan sihat (P<0.05). Kesemua SNP di dalam 
empat set data yang berbeza adalah di dalam keseimbangan Hardy-Weinberg 
(HWE) (P>0.05), kecuali bagi rs11091253 dalam set data pesakit schistosomiasis. 
Kajian hubung kait pesakit LF yang membawa genotip rs733618 AG (P= 0.02) dan 
pembawa alel minor (AG + GG) (P= 0.01) menunjukkan penurunan perbezaan yang 
sedikit terhadap risiko LF, setelah dibandingkan dengan genotip AA. Dikalangan kes 
asimptomatik amikrofilaraemik (AsAm), kaitan positif yang rendah diperolehi untuk 
setiap genotip dan varian bagi rs733618 dengan julat OR iaitu 0.27 – 0.45. Di dalam 
kes asimptomatik mikrofilaraemik (AM) pula, rs231775 telah menunjukkan 
penurunan risiko yang sedikit signifikan dengan julat OR iaitu 0.50 – 0.57. Dalam 
kumpulan schistosomiasis pula, rs733618 telah menunjukkan peningkatan yang 
 xiv
 xv
signifikan terhadap risiko infeksi (P= 0.012). Kesemua kohort telah memberikan 
empat haplotip yang serupa (>5%) apabila dilakukan pengiraan dengan 
Expectation-Maximization (EM)-Algorithm. Walau bagaimanapun, tiada hubung kait 
yang signifikan diperolehi antara haplotip dengan LF mahupun schistosomiasis. 
Kajian ini telah mengenalpasti SNP di dalam promoter gen CTLA-4 yang mungkin 
secara fungsinya mempunyai hubungan dengan kecenderungan kepada LF dan 
schistosomiasis. 
GENOTYPING OF SINGLE NUCELOTIDE POLYMORPHISMS (SNPs) OF CTLA-4 
AND FOXP3 GENES IN LYMPHATIC FILARIASIS AND SCHISTOSOMIASIS 
 
ABSTRACT 
 
 Lymphatic filariasis (LF) is a chronic parasitic disease caused by thread-like worms 
of Brugia and Wuchereria species that live in the human lymphatic system. It is a 
major cause of permanent disability and disfigurement in the endemic areas. 
Schistosomiasis is another chronic condition caused by schistosoma species which 
remains as a prevalent parasitic disease worldwide; it causes damage to internal 
organs and impair growth in children. Susceptibility to infections and disease 
severities are associated with a wide range of human genetic variations. However 
such association has not been well investigated especially with regard to CTLA-4 
and FoxP3 genes expressed by Tregs, for their functional roles and contributions to 
the risk of chronic helminth infections.  SNP genotyping approach was used in this 
study to identify potential SNPs in LF caused by Brugia malayi and schistosomiasis 
caused by Schistosoma haematobium. Briefly the methodology involved extraction 
and quantification of DNA samples from both parasitic diseases and healthy controls 
from the endemic areas. Subsequently, using five SNPs in CTLA-4 gene and one 
SNP in FoxP3 gene, samples for positive controls were selected by performing 
small scale real-time PCR genotyping on ten samples followed by confirmation by 
DNA sequencing. This was followed by large scale genotyping of all samples. 
Finally, analyses of the genotypes were performed using several statistical methods. 
Genotype confirmation by direct sequencing of three positive controls namely 
6944W, 6725H and 20M was found to be identical with real-time PCR. Out of six 
positive control samples, four samples (6725H, 6944W, 8209H and 20M) with 
insufficient DNA material were successfully cloned. Plasmid sequencing and 
chromatogram analysis confirmed the expected genotypes. Large scale genotyping 
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was successfully performed on 571 patient and healthy control samples. Using chi-
square test for allele frequency analysis, significant increase of rs733618A carriers 
was found in patients with LF compared with healthy control individuals (P=0.032). 
Out of five SNPs from schistosomiasis group, rs5742909 was found not be 
statistically significant when compared with healthy controls. Genotype distributions 
showed significant difference (P= 0.013) between LF patients and healthy controls 
for the rs733618. Meanwhile for samples from the schistosomiasis endemic area, 
the odd ratios (ORs) for the genotype distributions of all SNPs except rs16840252 
and rs231775 increased from 0.61 to 5.65 in patients when compared with healthy 
controls (P<0.05). All SNPs in four different datasets were in Hardy-Weinberg 
Equilibrium (HWE) (P>0.05) except for the rs11091253 in schistosomiasis patients. 
Association studies revealed that LF carriers of the rs733618 AG genotypes         
(P= 0.02) and minor allele carriers (AG + GG) (P= 0.01) showed significant 
decrease risk for LF. Among the asymptomatic amicrofilaraemic (AsAm) cases, 
positive associations were found for all genotypes and variants of rs733618 with 
ORs ranging from 0.27 to 0.45. In the asymptomatic microfilaraemic (AM) cases, 
rs231775 showed significant decrease in risk with ORs ranging from 0.50 to 0.57. In 
schistosomiasis population, rs733618 showed significant increase in the risk for 
infection (P= 0.012). All cohorts harbored the same four common haplotypes (>5%) 
when computed with Expectation Maximization (EM) Algorithm. Nevertheless, there 
was no statistical significant association between haplotypes and LF or 
schistosomiasis. The study has identified SNPs in CTLA-4 promoter gene that may 
be functionally linked with susceptibility to LF and schistosomiasis. 
 
 
CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Introduction to lymphatic filariasis 
1.1.1 Lymphatic filariasis 
Commonly known as elephantiasis, lymphatic filariasis (LF), is a devastating 
parasitic infection spread by mosquitoes. LF is caused by thread-like 
parasitic worms that can live for years inside human body and thrive in 
human lymphatic systems. Although it does not kill, the 1998 World Health 
Report ranked LF as the fourth leading cause of permanent disability (WHO, 
1998). This disease is widespread and occurs throughout the tropical and 
sub-tropical regions of the world, such as Asia, the Pacific, Africa and the 
Americas (Figure 1.1). It is endemic in over 80 countries and 1.1 billion 
people are at risk of infection, 120 million people worldwide are already 
affected by the disease and about 40 million of those affected suffer 
debilitating disabilities (WHO, 1997). Statistics have shown that over 25 
million men suffered from the genital form of the disease, while more than 15 
million of people suffered from lymphoedema or elephantiasis of the leg 
(WHO, 2009). Out of this, 90% of the cases are caused by Wuchereria 
bancrofti whereas Brugia malayi accounts for about 10% (or 13 million) of the 
infected people especially in South and Southeast Asia, South Korea, and 
parts of China. However, Brugia timori is only restricted to Timor Leste and a 
few islands in Indonesia (Michael, 2000). The World Health Organization 
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  Figure 1.1  World endemic countries for lymphatic filariasis in 2006 
      Source:http://gamapserver.who.int/mapLibrary/app/searchResults.aspx
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(WHO) in 1998 announced that LF is one of only six eradicable or potentially 
eradicable diseases and this was the stimulus that led to the current global 
campaign against LF (WHO, 1998). Consequently, a global programme for 
elimination of the disease known as the ‘Global Programme to Eliminate 
Lymphatic Filariasis’ (GPELF) was initiated in year 2000. 
 
Patients with chronic manifestation are prevented from experiencing normal 
working and social life because of physiological consequences and obvious 
physical handicap. It is primarily a disease of the poor because of its 
prevalence in remote rural areas and the underprivileged periurban and 
urban areas and consequently reduces ability people to work, resulting in 
loss of family income. Thus, LF imposes an economic burden on infected 
individuals, their household, and the communities in which they live. 
Ultimately, LF is a disease that perpetuates the poverty cycle. 
 
1.1.2 Transmission and life cycle 
There are three lymphatic filarial that infect human namely Wuchereria 
bancrofti, Brugia malayi and Brugia timori. The disease is being transmitted 
to human by the bite of more than 70 species and subspecies of mosquitoes 
mainly Anopheles, Aedes, Culex and Mansonia; hence it is referred to as a 
vector-borne disease (Stone et al., 1959; Nanduri & Kazura, 1989). The three 
lymphatic filariae have similar biphasic life cycle where larval development 
takes place in mosquito (intermediate host) and adult development takes 
place in the human (definitive host). Basically, there are four different stages 
of the life cycle of lymphatic filaria as depicted in Figure 1.2.  
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Figure 1.2 The life cycle of Brugia malayi 
      Source: www.dpd.cdc.gov/dpdx   
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Mosquito ingests microfilariae (mf) as part of its blood meal. Within a few 
hours, the mf penetrates the mosquito gut wall, migrates to the flight muscles 
and molts to the second larval stage (L2). The L1 and L2 molt takes place 
between days 6 to 10 depending on the environmental conditions. After 
several days, the parasite undergoes an additional molt to the L3 parasite. 
The L3 then migrates from the flight muscles to the mouth parts of the vector, 
where they are positioned to be passed on to the vertebrate host during a 
subsequent blood meal (Scott, 2000).  
 
Infection is initiated by the deposition of the third stage larvae (L3) on the skin 
of human host following a bite by an infective mosquito. In the definitive host, 
the larval undergo an additional molt to the fourth larval stage (L4) between 
days 9 and 14 post-infection as they mature into the lymphatic-dwelling adult 
male and female worms to complete the life cycle. Adult female parasites can 
remain reproductively active for more than 5 years. The lymphatic-dwelling 
filariae are diecious and undergo ovoviviparous reproduction resulting in the 
release of fully formed, sheathed first stage larvae (L1 or mf) from the female. 
Then, the mf enter the peripheral circulation of the human host where they 
are available to be ingested by the vector during a blood meal (Scott, 2000).  
 
The unique characteristic of the mf stage of the parasites is that they have 
“periodicity” that restricts their appearance in the blood to only certain periods 
of the day. In general, the mf can be classified into two main groups based 
on their circadian rhythms; i) the noctural periodic strain, ii) the nocturnaly 
subperiodic strain. In the nocturnally periodic strain, they virtually disappear 
from the peripheral circulation and are found predominantly in the blood 
vessels of lungs and deep tissues during the daytime. Conversely, during the 
night time (especially between 10 pm until 2 am), the mf can be found in the 
peripheral blood. Meanwhile, for the nocturnally subperiodic strain, the mf is 
present in the blood both day and night but the density is much more higher 
during the night and lose their sheath in the process of drying on microscope 
slides (Bowman et al., 2002). In addition to this basic strain, there is also 
nonperiodic or diurnally subperiodic strain of mf found in the South Pacific 
where it is transmitted mainly by day-biting mosquitoes of genus Aedes 
(Nanduri & Kazura, 1989).  
 
In Malaysia, the predominant strain is the nocturnal subperiodic B. malayi. 
Due to its predominant appearance in blood at night, conventional diagnostic 
method is by microscopic examination of night blood. Studies of Wuchereria 
and Brugia species suggested that their periodicity is due to the difference in 
the oxygen tension between the arterial and venous blood in the lungs 
(Hawking & Gammage, 1968; Burren, 1972; Nanduri & Kazura, 1989).  They 
suggested that if the difference in the arterial-venous oxygen tension is <50 
millimeters of mercury (mm Hg), mf were accumulated in lungs and when 
oxygen tension exceeds 50 mm Hg during sleep, mf migrated from the 
pulmonary vasculature and appeared in the peripheral circulation. However, 
Wang and Saz (1974) suggested that these parasites have adapted their 
periodicity to the vector feeding behavior, possibly to facilitate their 
transmission (Nanduri & Kazura, 1989). 
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1.1.3 Brugia malayi 
Brugian filariasis is caused by Brugia malayi and Brugia timori infection and it 
is endemic in parts of India, China, Indonesia, Philippines, Thailand, Vietnam, 
South Korea and Malaysia (WHO, 1998). However, China and South Korea 
have been recently certified as having eliminated the disease. This species 
was first identified by Lichtenstein and named by Brug in 1927. The B. malayi 
species is classified under the family of Filariidae and the genus of Brugia. 
The distribution of B. malayi is very similar to that of W. bancrofti. However, 
the differences between W. bancrofti, B. malayi and B. timori reside in their 
epidemiology, vectors, reservoirs, symptoms, but mainly the species 
morphology.  
 
The brugia female worm measures 43 to 55 mm in length by 130 to 170 μm 
in width, and male worm measures 13 to 23 mm in length by 70 to 80 μm in 
width.  Adult worms produce microfilariae, measuring 177 to 230 μm in length 
and 5 to 7 μm in width (Figure 1.3), which are sheathed 
(http://www.dpd.cdc.gov). The adult male and female worms of B. malayi 
inhabit primarily the lumen of lymphatics whereby the microfilariae usually 
migrate from the lymphatics into the blood stream (Nanduri & Kazura, 1989).  
 
In Malaysia, repetition subperiodic strains of B.malayi is principally 
transmitted by mosquitoes such as Mansonia annulata, Mansonia annulifera, 
Mansonia longiplapis and Mansonia annulifera acting as secondary vectors 
(Lim, 2005). Generally, brugian filariasis leads to symptoms and 
manifestations that may include recurrent fever, lymphatic damage, renal  
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  Figure 1.3 Microfilaria of Brugia malayi  
 
Source : http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Filariasis_il.htm 
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damage, adenolymphangitis, lymphoedema, elephantiasis and pulmonary 
disease. However, the infection is usually limited to legs below the knee and 
upper limbs distal to elbow.  
 
1.1.4 Clinical manifestation 
Lymphatic filariasis is characterized by a wide range of clinical presentation. 
Clinical features and pathology of lymphatic filariasis depend on the sites 
occupied by developing and mature worms, the number of worms present, 
length of infection and the immune responses of the host especially to 
damaged and dead worms. In areas where LF is endemic, infections can be 
asymptomatic, acute and chronic. The clinical manifestations of LF vary from 
one endemic area to another and also differ to some extent on the species of 
the parasite.  
 
Asymptomatic amicrofilaraemia individuals in the endemic community show 
no clinical manifestations or circulating microfilariae. This includes individuals 
with prepatent infection or adult worm infection without microfilaraemia. 
Microfilaraemic individuals are those with microfilariae circulating in their 
blood, and they may develop clinical manifestations (symptomatic 
microfilaraemia) or have no obvious clinical manifestations (asymptomatic 
microfilaraemia). Some of asymptomatic microfilaraemia individuals may 
remain microfilaraemic and asymptomatic for years or even for the rest of 
their lives. In contrast, obvious symptomatic filarial disease manifests itself in 
both acute and chronic forms, and maybe with or without infection.  
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In the acute form of lymphatic filariasis, there are recurrent attacks of fever 
(filarial fever) often described as adenolymphangitis (ADL) with painful 
inflammation of the lymph nodes (lymphadenitis) and lymph ducts 
(lymphangitis). The lymphatics involved are those of the limbs, genital organ 
(spermatic cord) and breasts. In bancroftian filariasis, the lymph glands in the 
groin and lymphatics of the male genitalia are frequently affected. 
Inflammation of the spermatic cord and repeated attacks can lead to 
blockage of the spermatic lymph vessels, leading to accumulation of fluid in 
the scrotal sac which becomes distended (hydrocele). In brugian filariasis, 
the affected lymph nodes are mostly situated in the inguinal and axillary 
regions with inflammation of distal lymphatics (Cheesebrough, 2000). 
 
Chronic lymphatic filariasis is characterized by hydrocele, lymphoedema and 
elephantiasis. Hydrocele is the most common chronic manifestation in 
bancroftian filariasis. Microfilariae are rarely found in the blood of patients 
with hyrdocele or elephantiasis but can be found occasionally in hydrocele 
fluid. On the other hand, chronic lympoedema progressing to elephantiasis is 
a complication of advanced lymphatic filariasis and most commonly affect the 
legs. The arms, scrotum, penis, vulva and breasts are more rarely affected. 
Following recurrent episode of acute attacks, first pitting oedema and then 
chronic non-pitting oedema with loss of skin elasticity and fibrosis develops. 
In the leg, loss of contour is first observed around the ankle. Over several 
years the oedema becomes non-pitting with thickening and loss of skin 
elasticity. Further progression leads to evident elephantiasis with skin folds, 
dermatosclerosis and papillomatus lesions. Secondary bacterial and fungal 
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infections are common in the lymphoedematous skin, and probably 
exarcerbate the progression of elephantiasis. In severe case pus may ooze 
from chronis ulceration in the effected part, which may also emanate a foul 
smell (Simonsen, 2008). 
 
1.1.5 Diagnosis of lymphatic filariasis 
The diagnosis of brugian LF caused by B. malayi and B. timori can be 
performed using conventional laboratory methods such as thick blood smear 
technique, DNA-based laboratory assay using the PCR technique, 
ultrasonography and immunoassays. For thick blood smear technique, 60 μl 
of blood is spread onto the slide, dried, stained and examined under the 
microscope for the presence of microfilariae. This method is insensitive for 
active infections; it misses people with low mf counts and those with 
amicrofilaremic infections; these individuals have the potential to contribute to 
future transmission. In addition, night blood collection is troublesome to both 
the staff and villagers and impractical in some endemic areas (Weil & Ramzy, 
2006). The sensitivity of this technique can be improved by membrane 
filtration of 1-5 ml of blood prior to microscopy.  
 
Molecular diagnostics by PCR is available for LF diagnosis. The main 
obstacle with the PCR method is that it requires sophisticated laboratory 
equipment and trained personnel to perform the analysis; and requires 
several hours to obtain the results. Thus, it is not practical to be used with 
large number of samples and for field screening. In addition, PCR generally 
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do not detect people with amicrofilaraemic infection and still requires night 
blood smear for maximum sensitivity.  
 
 Ultrasonography, the detection is based on ‘filarial dance sign’ which refers 
to live adult worm inside the lymphatic vessels. Other than not suitable for 
large scale studies, it is not very useful for brugian filariasis in which the adult 
worms are not found in the peripheral lymphatics.  
 
Immunoassays detect the presence of specific antigens or antibodies in the 
blood of individuals. Antigen detection assay is not available for brugian 
filariasis. With regard to detection of specific antibodies, it was recognized 
that the elevated levels of IgG4 is a marker of active infection rather than 
past exposure and it does not cross-react with antigens from non-filarial 
helminthes (Lal & Ottesen, 1988; Kwan-Lim et al., 1990; Turner et al., 1993; 
Haarbrink et al., 1995, Chanteau et al., 1995; Terhell et al., 1996; Rahmah et 
al., 1998). To date, there are two commercialized rapid tests for diagnosis of 
brugian lymphatic filariasis which is based on detection of anti-filarial IgG4 
antibody test namely Brugia RapidTM and PanLF RapidTM. The latter can be 
used for detection of both brugian and bancroftian filariasis. 
 
Brugia RapidTM is a novel test for rapid detection of brugian filariasis. The test 
is based on the use of the BmR1 recombinant antigen derived from the 
specific Bm17DIII gene of B. malayi. In laboratory evaluations and field 
studies, Brugia RapidTM has been shown to be highly sensitive (>95%) and 
specific (≥99%) for detection of B. malayi and B. timori infections, although it 
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also cross-reacts with some W. bancrofti positive sera (Rahmah et al., 2001, 
Lim et al., 2001, Rahmah et al., 2003, Lammie et al., 2004, Supali et al., 
2004, Jamail et al., 2005, Fischer et al., 2005, Melrose et al., 2006, Shenoy 
et al., 2007). In a field trial in Malaysia, which is a low endemic area, Brugia 
RapidTM detects about 9-10 times more positive cases than parasitological 
diagnosis through use of night blood smear (Jamail et al., 2005), while in the 
high endemic area of Indonesia, Brugia RapidTM shows an increase in 
detection of about three times (Supali et al., 2004). 
 
Similar to the Brugia RapidTM for IgG4 antibodies detection, the PanLF 
RapidTM test combined two recombinant antigens namely BmR1 and 
BmSXP; the latter is derived from SXP1 gene isolated from B. malayi adult 
worm cDNA library for detection of bancroftian filarial infections. Therefore, it 
can be used to detect all three species of filariasis i.e B. malayi, B. timori and 
W. bancrofti. A multicenter international evaluation of PanLF RapidTM 
conducted at five institutions showed an overall high sensitivity (96.5%) and 
overall specificity of 99.6% (Rahmah et al., 2007). 
 
1.1.6 Treatment of lymphatic filariasis 
The chemical 1-diethylcarbamyl-4-methylpiperazine hydrocholide was first 
synthesized in 1947 and first used as a treatment for lymphatic filariasis 
(Santiago-stevenson et al., 1947). Now known as diethylcarbamazine (DEC), 
it was quickly accepted as the standard treatment for lymphatic filariasis and 
until today, DEC still remains the best drug that is generally available for the 
treatment and prevention with filariasis (WHO, 1995). It has both 
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microfilaricidal and macrofilaricidal activities, but some adult worms may 
survive even after repeated courses of therapy. 
 
The drug is taken orally (tablet 50 mg, 100 mg) in the form of dihydrogen 
citrate under the brand names Hetrazan, Banocide and Notezine, and is 
reported to be stable even under extreme heat such as autoclaving or 
cooking (Gelband, 1994). It is almost completely absorbed after oral 
administration and is widely distributed in non-fatty tissue. It is rapidly and 
extensively metabolized and the residuum is recovered unchanged in the 
urine within 48 hours. The plasma half-life is usually within 6-12 hours (WHO, 
1995). DEC’s mode of action is still poorly understood. Somehow, it alters the 
surface membranes of supposedly unrecognizable microfilariae in the blood 
into antigenic foreign bodies easily detectable by the host immune system 
(Lim, 2005). 
 
Addiss and Dreyer (2000) recommended that DEC should be part of the 
treatment regiment given to all patients who exhibit clinical manifestation(s) 
of lymphatic filariasis. It is widely accepted that total cumulative dosage of 72 
mg/kg are necessary to eliminate W. bancrofti infections. Lower dosages are 
recommended by some authorities for treating B. malayi and B. timori 
infections. Annual mass treatment with single-dose DEC and albendazole is 
the central strategy for the Global Programme to Eliminate Filariasis 
(GPELF). Full course DEC should be reserved for patients who have 
evidence of active infection with lymphatic filariasis, including those who are 
asymptomatic. For both the acute and chronic manifestations of lymphatic 
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filariasis, supportive or specific clinical care is important (Addiss & Dreyer, 
2000). 
 
1.2 Introduction to schistosomiasis 
1.2.1 Schistosomiasis 
Schistosomiasis also known as bilharzias, bilharziosis or snail fever, remains 
one of the most prevalent parasitic diseases in the world. It is caused by 
helminth parasites of the genus Schistosoma. More than 200 million 
individuals infected, of whom over half suffer from related morbidity 
(Steimann et al., 2006). Whilst the global burden of schistosomiasis has been 
estimated at 1.7 to 4.5 disability-adjusted life years (DALYs) (WHO 2002, 
WHO 2004), new research suggests this is a considerable underestimation of 
the ‘true’ burden of schistosmoniasis (King et al., 2005; Jia et al., 2007). This 
disease is commonly found in Africa, the Caribbean, eastern South America, 
East Asia and in the Middle East, especially in areas where the water 
contains numerous freshwater snails, which may carry the parasite (Figure 
1.4). Schistosoma mansoni, Schistosoma haematobium and Schistosoma 
intercalatum are distributed throughout Africa, while Schistosoma japonicum 
is found in Southeast Asia and parts of China. Another species namely 
Schistosoma mekongi is mainly found in Cambodia and Laos. An estimated 
85% of the world’s cases of schistosomiasis are in Africa, where prevalence 
rates can exceed 50% of local populations (Chitsulu et al., 2000). Statistics 
have shown that 70 million may have heamaturia associated with S. 
haematobium infection, 18 million major bladder wall pathology and 10 
million hydronephrosis. It is estimated that kidney failure 
   Figure 1.4  World endemic countries for schistosomiasis 
     Source: http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/schistosomiasis.aspx     
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due to S. haematobium causes 150 000 deaths each year; and portal 
hypertension due to S. mansoni produces 130 000 fatalities annually (WHO, 
2006).  
 
School-age children are most likely to become infected with this silent, 
destructive disease because it is easily contracted while playing, bathing and 
swimming in water contaminated with the Schistosoma parasite, which is 
shed from snails and infects by penetrating human skins. However, 
schistosomiasis also can be transmitted simply through contact with 
contaminated water while performing daily chores such as washing laundry 
and herding animals. The 400 million school-age children who are infected 
(WHO, 2001) are often physically and intellectually compromised by anemia, 
leading to attention deficits, learning disabilities, school absenteeism and 
higher drop out rates. The failure to treat school-age children therefore 
hampers child development, yields a generation of adults disadvantaged by 
irreversible sequelae of infection, and compromises the economic 
development of communities and nations. For communities already burdened 
by poverty and ravaged by scourges such as malaria and HIV/AIDS, 
schistosomiasis is especially devastating. 
 
1.2.2 Transmission and life cycle 
There are three main species of Schistosoma namely S. haematobium,       
S. mansoni and S. japonicum which are responsible for the majority of 
schistosomiasis infection in human while the other two species, S. mekongi 
and S. intercalatum parasitize humans to a much lesser extent and more 
 17
localized geographically. This disease is being transmitted through contact 
with fresh water that contains infective cercariae released from an 
intermediate host snail. The snail intermediate hosts are species-specific; 
Bulinus spp. in S. haematobium, Biomphalaria spp. in S. mansoni and 
Oncomelania spp. in S. japonicum (Webber, 2009). The life cycle of all five 
human schistosomes, as shown in Figure 1.5, are broadly similar where 
larvae development takes place in freshwater snails (intermediate host) and 
adult development takes place in the human (definitive host).  
 
Parasite eggs are released into the environment from infected individuals, 
rupturing on contact with fresh water to release the free-swimming 
miracidium. Miracidia infect fresh-water snails by penetrating the snail's foot. 
After infection, close to the site of penetration, the miracidium transforms into 
a primary (mother) sporocyst. Germ cells within the primary sporocyst will 
then begin dividing to produce secondary (daughter) sporocysts, which 
migrate to the snail's hepatopancreas. Once at the hepatopancreas, germ 
cells within the secondary sporocyst begin to divide again, this time 
producing thousands of new parasites, known as cercariae, which are the 
larvae capable of infecting mammals. 
 
Cercariae emerge daily from the snail host in a circadian rhythm, dependent 
on ambient temperature and light. Young cercariae are highly motile, 
alternating between vigorous upward movement and sinking to maintain their 
position in the water. Cercarial activity is particularly stimulated by water 
turbulence, shadows and human skin chemicals. Penetration of the human  
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  Figure 1.5 Life cycle of Schistosoma spp.  
 
Source:http://www.dpd.cdc.gov/dpdx/HTML/Schistosomiasis.htm 
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